Scourinium effect across the axial spondyloarthritits spectrum at 1 year

Introduction: The MEASURE trials are a series of randomized, placebo-controlled Phase 3 trials conducted to evaluate the efficacy and safety of secukinumab, a biologic medicine, in patients with axial spondyloarthritis (axSpA) of different disease severity.

Methods: The MEASURE trials included patients with active axial spondyloarthritis (fusion of the bones), including ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA), who were naive to anti-TNF therapy. The primary endpoint was the proportion of patients achieving ASDAS-40 at week 52.

Results: Among patients with AS, 40% of those treated with secukinumab achieved ASDAS-40 at week 52, compared to 20% of those treated with placebo. Similar results were observed in patients with nr-axSpA.

Conclusion: Secukinumab demonstrated significant improvements in disease activity across the axSpA spectrum, supporting its use as a treatment option for patients with this condition.

Acknowledgments: This research was supported by Novartis Pharma AG, Basel, Switzerland.